The DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.
Real-World Adherence and Persistence to Direct Oral Anticoagulants in Patients With Atrial Fibrillation: A Systematic Review and Meta-Analysis
Abstract
Background: Stroke reduction with direct oral anticoagulants (DOACs) in atrial fibrillation (AF) is dependent on adherence and persistence in the real-world setting. Individual study estimates of DOAC adherence/persistence rates have been discordant. Our aims were to characterize real-world observational evidence for DOAC adherence/persistence and evaluate associated clinical outcomes in patients with AF. Methods and Results: PubMed, EMBASE, and CINAHL were searched from inception to June 2018. Observational studies that reported real-world DOAC adherence/persistence in patients with AF were included. Study quality was assessed using the Newcastle-Ottawa Scale. Meta-analyses for pooled estimates were performed using DerSimonian and Laird random-effects models. Outcomes included DOAC mean proportion of days covered or medication possession ratio, proportion of good adherence (proportion of days covered/medication possession ratio ≥80%), persistence, DOAC versus vitamin K antagonists persistence, and clinical outcomes associated with nonadherence/nonpersistence. Forty-eight observational studies with 594 784 unique patients with AF (59% male; mean age 71 years) were included. The overall pooled mean proportion of days covered/medication possession ratio was 77% (95% CI, 75%–80%), proportion of patients with good adherence was 66% (95% CI, 63%–70%), and proportion persistent was 69% (95% CI, 65%–72%). The pooled proportion of patients with good adherence was 71% (95% CI, 64%–78%) for apixaban, 60% (95% CI, 52%–68%) for dabigatran, and 70% (95% CI, 64%–75%) for rivaroxaban. Similar patterns were found for pooled persistence by agent. The pooled persistence was higher with DOACs than vitamin K antagonists (odds ratio, 1.44 [95% CI, 1.12–.86]). DOAC nonadherence was associated with an increased risk of stroke (hazard ratio, 1.39 [95% CI, 1.06–1.81]). Conclusions: Suboptimal adherence and persistence to DOACs was common in patients with AF, with 1 in 3 patients adhering to their DOAC <80% of the time, which was associated with poor clinical outcomes in nonadherent patients. Although it is convenient that DOACs do not require laboratory monitoring, greater effort in monitoring for and interventions to prevent nonadherence may be necessary to optimize stroke prevention. Increased clinician awareness of DOAC nonadherence may help identify at-risk patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Retracted: Predictive Validity of a Medication Adherence Measure in an Outpatient Setting
Morisky, D. E., Ang, A., Krousel‐Wood, M., & Ward, H. J. (2008) · The Journal of Clinical Hypertension · doi:10.1111/j.1751-7176.2008.07572.x · Cited by 2,877
RetractedMeasuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
Bias in meta-analysis detected by a simple, graphical test
Egger, M., Smith, G. D., Schneider, M., & Minder, C. (1997) · BMJ · doi:10.1136/bmj.315.7109.629 · Cited by 56,722
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552
Meta-analysis of Observational Studies in Epidemiology<SUBTITLE>A Proposal for Reporting</SUBTITLE>
Stroup, D. F. (2000) · JAMA · doi:10.1001/jama.283.15.2008 · Cited by 20,623
Duval, S., & Tweedie, R. (2000) · Biometrics · doi:10.1111/j.0006-341x.2000.00455.x · Cited by 14,099
Dabigatran versus warfarin in patients with atrial fibrillation
Connolly, S. J., Ezekowitz, M. D., Yusuf, S., Eikelboom, J., Oldgren, J., Parekh, A., Pogue, J., Reilly, P. A., Themeles, E., Varrone, J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0905561 · Cited by 11,215
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation
Patel, M. R., Mahaffey, K. W., Garg, J., Pan, G., Singer, D. E., Hacke, W., Breithardt, G., Halperin, J. L., Hankey, G. J., Piccini, J. P., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009638 · Cited by 9,430
Apixaban versus warfarin in patients with atrial fibrillation
Granger, C. B., Alexander, J. H., McMurray, J. J. V., Lopes, R. D., Hylek, E. M., Hanna, M., Al-Khalidi, H. R., Ansell, J., Atar, D., Avezum, A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107039 · Cited by 8,943
Concurrent and Predictive Validity of a Self-reported Measure of Medication Adherence
Morisky, D. E., Green, L. W., & Levine, D. M. (1986) · Medical Care · doi:10.1097/00005650-198601000-00007 · Cited by 5,317
Edoxaban versus warfarin in patients with atrial fibrillation
Giugliano, R. P., Ruff, C. T., Braunwald, E., Murphy, S. A., Wiviott, S. D., Halperin, J. L., Waldo, A. L., Ezekowitz, M. D., Weitz, J. I., Špinar, J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1310907 · Cited by 5,164
Worldwide Epidemiology of Atrial Fibrillation: A Global Burden of Disease 2010 Study
Chugh, S. S., Havmoeller, R., Narayanan, K., Singh, D., Rienstra, M., Benjamin, E. J., Gillum, R. F., Kim, Y.-H., McAnulty, J. H., Zheng, Z.-J., et al. (2014) · Circulation · doi:10.1161/circulationaha.113.005119 · Cited by 4,506
How should meta‐regression analyses be undertaken and interpreted?
Thompson, S. G., & Higgins, J. P. T. (2002) · Statistics in Medicine · doi:10.1002/sim.1187 · Cited by 3,026
A systematic review of the associations between dose regimens and medication compliance
Claxton, A. J., Cramer, J., & Pierce, C. (2001) · Clinical Therapeutics · doi:10.1016/s0149-2918(01)80109-0 · Cited by 2,388
Investigating and dealing with publication and other biases in meta-analysis
Sterne, J. A. C., Egger, M., & Smith, G. D. (2001) · BMJ · doi:10.1136/bmj.323.7304.101 · Cited by 2,225
January, C. T., Wann, L. S., Calkins, H., Chen, L. Y., Cigarroa, J. E., Cleveland, J. C., Ellinor, P. T., Ezekowitz, M. D., Field, M. E., Furie, K. L., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.01.011 · Cited by 2,205
Colilla, S., Crow, A., Petkun, W., Singer, D. E., Simon, T., & Liu, X. (2013) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2013.05.063 · Cited by 1,321
Siontis, K. C., Zhang, X., Eckard, A., Bhave, N., Schaubel, D. E., He, K., Tilea, A., Stack, A. G., Balkrishnan, R., Yao, X., et al. (2018) · Circulation · doi:10.1161/circulationaha.118.035418 · Cited by 492
Yao, X., Abraham, N. S., Alexander, G. C., Crown, W., Montori, V. M., Sangaralingham, L. R., Gersh, B. J., Shah, N. D., & Noseworthy, P. A. (2016) · Journal of the American Heart Association · doi:10.1161/jaha.115.003074 · Cited by 452
Baker, W. L., Cios, D. A., Sander, S. D., & Coleman, C. I. (2009) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2009.15.3.244 · Cited by 411
Kimmel, S. E. (2007) · Archives of Internal Medicine · doi:10.1001/archinte.167.3.229 · Cited by 290
Shore, S., Carey, E. P., Turakhia, M. P., Jackevicius, C. A., Cunningham, F., Pilote, L., Bradley, S. M., Maddox, T. M., Grunwald, G. K., Barón, A. E., et al. (2014) · American Heart Journal · doi:10.1016/j.ahj.2014.03.023 · Cited by 226
Self-citationLaliberté, F., Cloutier, M., Nelson, W. W., Coleman, C. I., Pilon, D., Olson, W. H., Damaraju, C. V., Schein, J. R., & Lefebvre, P. (2014) · Current Medical Research and Opinion · doi:10.1185/03007995.2014.907140 · Cited by 185
Katholing, A., Wallenhorst, C., Freedman, S. B., & Martinez, C. (2016) · Thrombosis and Haemostasis · doi:10.1160/th15-04-0350 · Cited by 173
Direct Oral Anticoagulants (DOACs) in the Laboratory: 2015 Review
Adcock, D. M., & Gosselin, R. (2015) · Thrombosis Research · doi:10.1016/j.thromres.2015.05.001 · Cited by 166
Lamberts, M., Stærk, L., Olesen, J. B., Fosbøl, E. L., Hansen, M. L., Harboe, L., Lefèvre, C., Evans, D., & Gislason, G. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.116.004517 · Cited by 165
Zalesak, M., Siu, K., Francis, K. M., Chen, Y. X., Alvrtsyan, H., Rao, Y., Walker, D. R., Sander, S. D., Miyasato, G., Matchar, D. B., et al. (2013) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.113.000192 · Cited by 163
Borne, R. T., O’Donnell, C. I., Turakhia, M. P., Varosy, P. D., Jackevicius, C. A., Marzec, L., Masoudi, F. A., Hess, P. L., Maddox, T. M., & Ho, P. M. (2017) · BMC Cardiovascular Disorders · doi:10.1186/s12872-017-0671-6 · Cited by 162
Self-citationGorst‐Rasmussen, A., Skjøth, F., Larsen, T. B., Rasmussen, L. H., Lip, G. Y. H., & Lane, D. A. (2015) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12845 · Cited by 157
Beyer‐Westendorf, J., EHLKEN, B., & Evers, T. (2016) · EP Europace · doi:10.1093/europace/euv421 · Cited by 152
Site-Level Variation in and Practices Associated With Dabigatran Adherence
Shore, S., Ho, P. M., Lambert‐Kerzner, A., Glorioso, T. J., Carey, E., Cunningham, F., Longo, L., Jackevicius, C. A., Rose, A. J., & Turakhia, M. P. (2015) · JAMA · doi:10.1001/jama.2015.2761 · Cited by 145
Self-citationEffect of dosing frequency on chronic cardiovascular disease medication adherence
Coleman, C. I., Roberts, M. S., Sobieraj, D. M., Lee, S., Alam, T., & Kaur, R. (2012) · Current Medical Research and Opinion · doi:10.1185/03007995.2012.677419 · Cited by 125
Forslund, T., Wettermark, B., & Hjemdahl, P. (2015) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-015-1983-z · Cited by 123
Early non-persistence with dabigatran and rivaroxaban in patients with atrial fibrillation
Jackevicius, C. A., Tsadok, M. A., Essebag, V., Atzema, C. L., Eisenberg, M. J., Tu, J. V., Lu, L., Rahme, E., Ho, P. M., Turakhia, M. P., et al. (2017) · Heart · doi:10.1136/heartjnl-2016-310672 · Cited by 98
Self-citationHernandez, I., Zhang, Y., & Saba, S. (2017) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2017.07.092 · Cited by 97
Manzoor, B. S., Lee, T. A., Sharp, L. K., Walton, S. M., Galanter, W. L., & Nutescu, E. A. (2017) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1989 · Cited by 88
Nelson, W. W., Song, X., Coleman, C. I., Thomson, E., Smith, D. M., Damaraju, C. V., & Schein, J. R. (2014) · Current Medical Research and Opinion · doi:10.1185/03007995.2014.933577 · Cited by 88
Maura, G., Pariente, A., Alla, F., & Billionnet, C. (2017) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.4268 · Cited by 72
Johnson, M. E., Lefèvre, C., Collings, S., Evans, D., Kloss, S., Ridha, E., & Maguire, A. (2016) · BMJ Open · doi:10.1136/bmjopen-2016-011471 · Cited by 65
Shah, A., Shewale, A. R., Hayes, C. J., & Martin, B. C. (2016) · Stroke · doi:10.1161/strokeaha.115.012325 · Cited by 64
Alberts, M. J., Peacock, W. F., Fields, L. E., Bunz, T. J., Nguyen, E., Milentijevic, D., Schein, J. R., & Coleman, C. I. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.03.212 · Cited by 63
Lip, G. Y. H., Pan, X., Kamble, S., Kawabata, H., Mardekian, J., Masseria, C., & Phatak, H. M. (2018) · PLoS ONE · doi:10.1371/journal.pone.0195950 · Cited by 56
Brown, J. D., Shewale, A. R., & Talbert, J. (2017) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2017.23.9.958 · Cited by 55
Persistence With Dabigatran Therapy at 2 Years in Patients With Atrial Fibrillation
Paquette, M., França, L. R., Teutsch, C., Diener, H., Lu, S., Dubner, S., Sheng, C., Rothman, K. J., Zint, K., Halperin, J. L., et al. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.07.793 · Cited by 54
Deshpande, C. G., Kogut, S. J., & Willey, C. J. (2018) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2018.24.5.430 · Cited by 54
Use of Non‐Vitamin K Antagonist Oral Anticoagulants 2008–2016: A Danish Nationwide Cohort Study
Haastrup, S. B., Hellfritzsch, M., Rasmussen, L., Pottegård, A., & Grove, E. L. (2018) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.13024 · Cited by 53
Sørensen, R., Nielsen, B. J., Pallisgaard, J. L., Lee, C. J., & Torp-Pedersen, C. T. (2017) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvw048 · Cited by 46
McHorney, C. A., Ashton, V., Laliberté, F., Germain, G., Wynant, W., Crivera, C., Schein, J. R., Lefèbvre, P., & Peterson, E. D. (2017) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2017.23.9.980 · Cited by 43
Adherence to a Novel Oral Anticoagulant Among Patients with Atrial Fibrillation
Zhou, M., Chang, H., Segal, J. B., Alexander, G. C., & Singh, S. (2015) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2015.21.11.1054 · Cited by 42
Maura, G., Billionnet, C., Alla, F., Gagne, J. J., & Pariente, A. (2017) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2046 · Cited by 41
Continuation of Dabigatran Therapy in “Real-World” Practice in Hong Kong
Ho, M.-H., Ho, C. W., Cheung, E. H.-L., Chan, P. H., Hai, J. J., Chan, K. H., Chan, E. W., Leung, G., Tse, H., & Siu, C. (2014) · PLoS ONE · doi:10.1371/journal.pone.0101245 · Cited by 40
Cutler, T., Chuang, A., Huynh, T. D., Witt, R. G., Branch, J. M., Pon, T. K., & White, R. (2014) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2014.20.10.1028 · Cited by 40
Treatment Changes among Users of Non‐Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation
Hellfritzsch, M., Husted, S., Grove, E. L., Rasmussen, L., Poulsen, B. K., Johnsen, S. P., Hallas, J., & Pottegård, A. (2016) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.12664 · Cited by 38
Coleman, C. I., Tangirala, M., & Evers, T. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.03.051 · Cited by 35
Collings, S., Lefèvre, C., Johnson, M. E., Evans, D., Hack, G., Stynes, G., & Maguire, A. (2017) · PLoS ONE · doi:10.1371/journal.pone.0185642 · Cited by 34
Simons, L. A., Ortiz, M. S., Freedman, B., Waterhouse, B. J., Colquhoun, D., & Thomas, G. (2016) · Current Medical Research and Opinion · doi:10.1080/03007995.2016.1218325 · Cited by 32
Mueller, T., Alvarez‐Madrazo, S., Robertson, C., & Bennie, M. (2017) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.4272 · Cited by 32
Bancroft, T., Lim, J. T., Wang, C., Sander, S. D., & Swindle, J. P. (2016) · Clinical Therapeutics · doi:10.1016/j.clinthera.2016.01.008 · Cited by 31
Comparison of Adherence to Rivaroxaban Versus Apixaban Among Patients With Atrial Fibrillation
McHorney, C. A., Peterson, E. D., Laliberté, F., Germain, G., Nelson, W. W., Crivera, C., Schein, J. R., & Lefèbvre, P. (2016) · Clinical Therapeutics · doi:10.1016/j.clinthera.2016.09.014 · Cited by 30
Dabigatran persistence and adherence in New Zealand: a nationwide retrospective observational study
Harper, P. L., Pollock, D., & Stephens, M. (2018) · BMJ Open · doi:10.1136/bmjopen-2017-020212 · Cited by 30
Douros, A., Renoux, C., Coulombe, J., & Suissa, S. (2017) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.4333 · Cited by 24
Collings, S., Vannier-Moreau, V., Johnson, M. E., Stynes, G., Lefèvre, C., Maguire, A., Asmar, J., Bizouard, G., Duhot, D., Mouquet, F., et al. (2018) · Archives of cardiovascular diseases · doi:10.1016/j.acvd.2017.10.003 · Cited by 18
Jacobs, M. S., Schouten, J. F., de Boer, P. T., Hoffmann, M., Levin, L., & Postma, M. J. (2018) · Current Medical Research and Opinion · doi:10.1080/03007995.2018.1459528 · Cited by 16
Gómez-Lumbreras, A., Cortés, J., Giner‐Soriano, M., Quijada-Manuitt, M. Á., & Morros, R. (2018) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248418778544 · Cited by 14
Annavarapu, S., Gandhi, P., Li, Y., Arora, P., Moretz, C., Wang, C., Sander, S. D., & Andrews, G. A. (2018) · Journal of Comparative Effectiveness Research · doi:10.2217/cer-2017-0081 · Cited by 8
Cited by
Heart Disease and Stroke Statistics—2023 Update: A Report From the American Heart Association
Tsao, C. W., Aday, A. W., Almarzooq, Z. I., Anderson, C. A. M., Arora, P., Avery, C. L., Baker-Smith, C. M., Beaton, A. Z., Boehme, A. K., Buxton, A. E., et al. (2023) · Circulation · doi:10.1161/cir.0000000000001123 · Cited by 8,300
Self-citationHeart Disease and Stroke Statistics—2022 Update: A Report From the American Heart Association
Tsao, C. W., Aday, A. W., Almarzooq, Z. I., Alonso, A., Beaton, A. Z., Bittencourt, M. S., Boehme, A. K., Buxton, A. E., Carson, A. P., Commodore-Mensah, Y., et al. (2022) · Circulation · doi:10.1161/cir.0000000000001052 · Cited by 5,987
Martin, S. S., Aday, A. W., Almarzooq, Z. I., Anderson, C. A. M., Arora, P., Avery, C. L., Baker-Smith, C. M., Barone Gibbs, B., Beaton, A. Z., Boehme, A. K., et al. (2024) · Circulation · doi:10.1161/cir.0000000000001209 · Cited by 2,800
Self-citationMartin, S. S., Aday, A. W., Allen, N. B., Almarzooq, Z. I., Anderson, C. A. M., Arora, P., Avery, C. L., Baker-Smith, C. M., Bansal, N., Beaton, A. Z., et al. (2025) · Circulation · doi:10.1161/cir.0000000000001303 · Cited by 1,080
Self-citationSenoo, K., Miki, T., Ohkura, T., Iwakoshi, H., Nishimura, T., Shiraishi, H., Teramukai, S., & Matoba, S. (2022) · JMIR mHealth and uHealth · doi:10.2196/30807 · Cited by 36
“A recent meta-analysis found that suboptimal adherence to and persistence with direct oral anticoagulants (DOACs) is common [6].”
Background
Metadata
- Authors
- Ozaki, A. F., Choi, A. S., Le, Q. T., Ko, D. T., Han, J. K., Park, S. S., & Jackevicius, C. A.
- Venue
- Circulation: Cardiovascular Quality and Outcomes
- Published
- 2020-03
- Volume
- 13
- Issue
- 3
- Pages
- e005969-e005969
- ISSN
- 1941-7705 (ISSN-L)
- 1941-7713
- OpenAlex
- W3012307018
- Cited by
- 258
- References
- 65
- FWCI
- 21.65
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.